奥克列珠单抗
医学
多发性硬化
美罗华
队列
内科学
肿瘤科
CD20
药品
物理疗法
免疫学
药理学
淋巴瘤
作者
M. Hay,Fabien Rollot,Romain Casey,Anne Kerbrat,Gilles Edan,Guillaume Mathey,Pierre Labauge,de Sèze,Sandra Vukusic,David Laplaud,Caroline Papeix,Thibault Moreau,Éric Thouvenot,Gilles Defer,Christine Lebrun‐Frénay,Jonathan Ciron,Eric Berger,Bruno Stankoff,Pierre Clavelou,Élisabeth Maillart
出处
期刊：Neurology
[Lippincott Williams & Wilkins]
日期：2024-09-25
卷期号：103 (8)
标识
DOI：10.1212/wnl.0000000000209886
摘要
Although rituximab failed to demonstrate a significant effect on disability progression in primary progressive multiple sclerosis (PPMS), ocrelizumab succeeded. Our main objective was to analyze confirmed disability progression (CDP) in a cohort of patients with PPMS treated with anti-CD20 therapies compared with a weighted untreated control cohort.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
Lignin
herococa
酷炫的咖啡豆
YifanWang
GingerF
helpmepaper
Billy
MchemG
小趴菜
Esther
从容芮
pcr163
YY
SI
遇上就这样吧
不瞌睡
竹筏过海
lmy
诸葛带你做分析_yorfir
脂肪小米粥
皖公网安备34019202002308
